ReviewFEMS yeast research2017
Designing microorganisms for heterologous biosynthesis of cannabinoids.
Review in FEMS yeast research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- Resurrected Ancestral Cannabis Enzymes Unveil the Origin and Functional Evolution of Cannabinoid Synthases.Plant biotechnology journal · 2026Article
- The Amoeba Dictyostelium discoideum as Novel Production Host for Complex Substances.Advances in biochemical engineering/biotechnology · 2025Review
- Cannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway.Drug design, development and therapy · 2025Article
- Rational Design and Modification of NphB for Cannabinoids Biosynthesis.Molecules (Basel, Switzerland) · 2024Article
- Advancement of Research Progress on Synthesis Mechanism of Cannabidiol (CBD).ACS synthetic biology · 2024Review
- Promoter engineering enables precise metabolic regulation towards efficient β-elemene production inSynthetic and systems biotechnology · 2024Article
- Integrated omics of Saccharomyces cerevisiae CENPK2-1C reveals pleiotropic drug resistance and lipidomic adaptations to cannabidiol.NPJ systems biology and applications · 2024Article
- Evaluating the Metabolomic Profile and Anti-Pathogenic Properties ofMetabolites · 2024Review
- Hemp-Derived CBD Used in Food and Food Supplements.Molecules (Basel, Switzerland) · 2023Review
- Article
- Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.Molecules (Basel, Switzerland) · 2023Review
- Scale-up of an amoeba-based process for the production of the cannabinoid precursor olivetolic acid.Microbial cell factories · 2022Article
- Semi-quantitative analysis of cannabinoids in hemp (Cannabis sativa L.) using gas chromatography coupled to mass spectrometry.Journal of cannabis research · 2022Article
- Screening microbially produced ΔNature communications · 2022Article
- Engineering the amoeba Dictyostelium discoideum for biosynthesis of a cannabinoid precursor and other polyketides.Nature biotechnology · 2022Article
- HarnessingJournal of natural products · 2022Review
- In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.Molecules (Basel, Switzerland) · 2022Article
- Review
- Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?Bioengineered · 2021Article
- Cannabinoids-Characteristics and Potential for Use in Food Production.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decade, the use of medical Cannabis has expanded globally and legislation is getting more liberal in many countries, facilitating the research on cannabinoids. The unique interaction of cannabinoids with the human endocannabinoid system makes these compounds an interesting target to be studied as therapeutic agents for the treatment of several medical conditions. However, currently there are important limitations in the study, production and use of cannabinoids as pharmaceutical drugs. Besides the main constituent tetrahydrocannabinolic acid, the structurally related compound cannabidiol is of high interest as drug candidate. From the more than 100 known cannabinoids reported, most can only be extracted in very low amounts and their pharmacological profile has not been determined. Today, cannabinoids are isolated from the strictly regulated Cannabis plant, and the supply of compounds with sufficient quality is a major problem. Biotechnological production could be an attractive alternative mode of production. Herein, we explore the potential use of synthetic biology as an alternative strategy for synthesis of cannabinoids in heterologous hosts. We summarize the current knowledge surrounding cannabinoids biosynthesis and present a comprehensive description of the key steps of the genuine and artificial pathway, systems biotechnology needs and platform optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.